EUVIMEDEUVIMED entdecken
Crossref

Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure

Kai-Chun Chang, Tung-Hung Su iD, Cho-Kai Wu, Shang-Chin Huang, Tai-Chung Tseng, Chun-Ming Hong, Shih-Jer Hsu, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao

European Journal of Heart Failure · 01.03.2025 · 27 (3) · 512-520

DOI: 10.1002/ejhf.3567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 08.01.2025. Verfasst von Kai-Chun Chang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Heart Failure, Fatty Liver. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Taiwan University Hospital, National Science and Technology Council, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by steatotic liver disease (SLD) and cardiometabolic factors, is increasing in prevalence, but its association with heart failure (HF) is unclear. Methods and results Patients with SLD without a history of HF from 2006 to 2021 were retrospectively included and were classified into MASLD and non-MASLD groups that were followed longitudinally. The primary outcome was the new development of HF, which was sub-classified by echocardiography. Multivariable and propensity score matching analyses were conducted to adjust for confounding factors. Overall, 26 676 patients with SLD were included, with a median age of 51 years and 71% classified as MASLD. During a median follow-up of 6 years, 429 (1.61%) patients developed HF, and 76% were HF with preserved ejection fraction (HFpEF). The risk of HF was significantly higher in patients with MASLD than in those without (sub-distribution hazard ratio [SHR] 2.59, 95% confidence interval [CI] 1.84–3.64) after adjustment of competing mortality. There was a dose-dependent increase in HF risks in patients with more cardiometabolic risk factors (SHR 1.12, 95% CI 1.04–1.22). MASLD was also associated with higher risk of HF-related hospitalization (SHR 2.30, 95% CI 1.31–4.04) and specifically, the risk of HFpEF (SHR 1.91, 95% CI 1.27–2.86). In propensity score-matched cohorts, MASLD was also associated with a 2.52-fold higher risk of HF.

Conclusion

In patients with SLD, those with MASLD show a higher risk of HF, specifically HFpEF. Future studies are warranted to validate the association between HF and MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureFatty LiverHumansMaleFemaleMiddle AgedRetrospective StudiesStroke VolumeEchocardiographyRisk FactorsFollow-Up StudiesAgedPropensity ScoreRisk Assessment

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseHeart failure with preserved ejection fractionNon‐alcoholic fatty liver diseaseSteatosis

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Tung-Hung Su

Förderung

  • National Taiwan University Hospital
  • National Science and Technology Council
  • Ministry of Health and Welfare
  • Liver Disease Prevention & Treatment Research Foundation, Taiwan

Zitieren

APA

Chang, K. C., Su, T. H., Wu, C. K., Huang, S. C., Tseng, T. C., Hong, C. M., Hsu, S. J., Liu, C. H., Yang, H. C., Liu, C. J., & Kao, J. H. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure. European Journal of Heart Failure, 27(3), 512-520. https://doi.org/10.1002/ejhf.3567

Vancouver

Chang KC, Su TH, Wu CK, Huang SC, Tseng TC, Hong CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure. European Journal of Heart Failure. 2025;27(3):512-520. doi:10.1002/ejhf.3567

BibTeX
@article{Chang2025,
  author = {Chang, Kai-Chun and Su, Tung-Hung and Wu, Cho-Kai and Huang, Shang-Chin and Tseng, Tai-Chung and Hong, Chun-Ming and Hsu, Shih-Jer and Liu, Chen-Hua and Yang, Hung-Chih and Liu, Chun-Jen and Kao, Jia-Horng},
  title = {Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {512--520},
  doi = {10.1002/ejhf.3567}
}
Kostenlos starten →